Advertisement
New Zealand markets closed
  • NZX 50

    12,777.09
    -68.55 (-0.53%)
     
  • NZD/USD

    0.6093
    -0.0020 (-0.32%)
     
  • NZD/EUR

    0.5575
    -0.0007 (-0.13%)
     
  • ALL ORDS

    8,538.30
    +46.80 (+0.55%)
     
  • ASX 200

    8,262.00
    +47.50 (+0.58%)
     
  • OIL

    74.67
    -0.89 (-1.18%)
     
  • GOLD

    2,672.50
    -3.80 (-0.14%)
     
  • NASDAQ

    20,271.97
    +30.17 (+0.15%)
     
  • FTSE

    8,253.65
    +15.92 (+0.19%)
     
  • Dow Jones

    42,863.86
    +409.76 (+0.97%)
     
  • DAX

    19,373.83
    +162.93 (+0.85%)
     
  • Hang Seng

    21,183.38
    -68.60 (-0.32%)
     
  • NIKKEI 225

    39,605.80
    +224.90 (+0.57%)
     
  • NZD/JPY

    90.9590
    -0.1840 (-0.20%)
     

A Look At The Intrinsic Value Of Insulet Corporation (NASDAQ:PODD)

Key Insights

  • Insulet's estimated fair value is US$206 based on 2 Stage Free Cash Flow to Equity

  • Insulet's US$230 share price indicates it is trading at similar levels as its fair value estimate

  • Analyst price target for PODD is US$237, which is 15% above our fair value estimate

Does the September share price for Insulet Corporation (NASDAQ:PODD) reflect what it's really worth? Today, we will estimate the stock's intrinsic value by taking the forecast future cash flows of the company and discounting them back to today's value. We will use the Discounted Cash Flow (DCF) model on this occasion. Don't get put off by the jargon, the math behind it is actually quite straightforward.

We generally believe that a company's value is the present value of all of the cash it will generate in the future. However, a DCF is just one valuation metric among many, and it is not without flaws. If you still have some burning questions about this type of valuation, take a look at the Simply Wall St analysis model.

View our latest analysis for Insulet

Crunching The Numbers

We are going to use a two-stage DCF model, which, as the name states, takes into account two stages of growth. The first stage is generally a higher growth period which levels off heading towards the terminal value, captured in the second 'steady growth' period. To start off with, we need to estimate the next ten years of cash flows. Where possible we use analyst estimates, but when these aren't available we extrapolate the previous free cash flow (FCF) from the last estimate or reported value. We assume companies with shrinking free cash flow will slow their rate of shrinkage, and that companies with growing free cash flow will see their growth rate slow, over this period. We do this to reflect that growth tends to slow more in the early years than it does in later years.

A DCF is all about the idea that a dollar in the future is less valuable than a dollar today, and so the sum of these future cash flows is then discounted to today's value:

10-year free cash flow (FCF) forecast

2025

2026

2027

2028

2029

2030

2031

2032

2033

2034

Levered FCF ($, Millions)

US$356.8m

US$439.0m

US$500.7m

US$553.7m

US$598.9m

US$637.6m

US$671.3m

US$701.1m

US$728.1m

US$753.3m

Growth Rate Estimate Source

Analyst x3

Analyst x2

Est @ 14.06%

Est @ 10.59%

Est @ 8.16%

Est @ 6.46%

Est @ 5.27%

Est @ 4.44%

Est @ 3.86%

Est @ 3.45%

Present Value ($, Millions) Discounted @ 6.5%

US$335

US$387

US$415

US$431

US$437

US$437

US$432

US$424

US$413

US$402

("Est" = FCF growth rate estimated by Simply Wall St)
Present Value of 10-year Cash Flow (PVCF) = US$4.1b

We now need to calculate the Terminal Value, which accounts for all the future cash flows after this ten year period. The Gordon Growth formula is used to calculate Terminal Value at a future annual growth rate equal to the 5-year average of the 10-year government bond yield of 2.5%. We discount the terminal cash flows to today's value at a cost of equity of 6.5%.

Terminal Value (TV)= FCF2034 × (1 + g) ÷ (r – g) = US$753m× (1 + 2.5%) ÷ (6.5%– 2.5%) = US$19b

Present Value of Terminal Value (PVTV)= TV / (1 + r)10= US$19b÷ ( 1 + 6.5%)10= US$10b

The total value is the sum of cash flows for the next ten years plus the discounted terminal value, which results in the Total Equity Value, which in this case is US$14b. The last step is to then divide the equity value by the number of shares outstanding. Compared to the current share price of US$230, the company appears around fair value at the time of writing. Remember though, that this is just an approximate valuation, and like any complex formula - garbage in, garbage out.

dcf
dcf

Important Assumptions

Now the most important inputs to a discounted cash flow are the discount rate, and of course, the actual cash flows. Part of investing is coming up with your own evaluation of a company's future performance, so try the calculation yourself and check your own assumptions. The DCF also does not consider the possible cyclicality of an industry, or a company's future capital requirements, so it does not give a full picture of a company's potential performance. Given that we are looking at Insulet as potential shareholders, the cost of equity is used as the discount rate, rather than the cost of capital (or weighted average cost of capital, WACC) which accounts for debt. In this calculation we've used 6.5%, which is based on a levered beta of 0.968. Beta is a measure of a stock's volatility, compared to the market as a whole. We get our beta from the industry average beta of globally comparable companies, with an imposed limit between 0.8 and 2.0, which is a reasonable range for a stable business.

SWOT Analysis for Insulet

Strength

  • Earnings growth over the past year exceeded the industry.

  • Debt is well covered by earnings and cashflows.

Weakness

  • Expensive based on P/E ratio and estimated fair value.

Opportunity

  • Annual revenue is forecast to grow faster than the American market.

Threat

  • Annual earnings are forecast to grow slower than the American market.

Next Steps:

Although the valuation of a company is important, it is only one of many factors that you need to assess for a company. DCF models are not the be-all and end-all of investment valuation. Instead the best use for a DCF model is to test certain assumptions and theories to see if they would lead to the company being undervalued or overvalued. If a company grows at a different rate, or if its cost of equity or risk free rate changes sharply, the output can look very different. For Insulet, there are three important factors you should explore:

  1. Risks: You should be aware of the 2 warning signs for Insulet we've uncovered before considering an investment in the company.

  2. Management:Have insiders been ramping up their shares to take advantage of the market's sentiment for PODD's future outlook? Check out our management and board analysis with insights on CEO compensation and governance factors.

  3. Other Solid Businesses: Low debt, high returns on equity and good past performance are fundamental to a strong business. Why not explore our interactive list of stocks with solid business fundamentals to see if there are other companies you may not have considered!

PS. The Simply Wall St app conducts a discounted cash flow valuation for every stock on the NASDAQGS every day. If you want to find the calculation for other stocks just search here.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.